Chronic Pulmonary Aspergillosis as a Considerable Complication in Post-Tuberculosis Lung Disease

Matthias J. Neuböck; Gunar Günther; Aleksandra Barac; Jesper R. Davidsen; Christian B. Laursen; Ritesh Agarwal; Inderpaul S. Sehgal; Christoph Lange; Helmut J.F. Salzer; for CPAnet

doi:10.1055/s-0043-1776913

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2024; 45(01): 102-113
DOI: 10.1055/s-0043-1776913

Review Article

Chronic Pulmonary Aspergillosis as a Considerable Complication in Post-Tuberculosis Lung Disease

Authors

Matthias J. Neuböck

¹Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine 4 - Pneumology, Kepler University Hospital, Linz, Austria

²Medical Faculty, Johannes Kepler University Linz, Linz, Austria

for CPAnet

Gunar Günther

³Department of Pulmonology and Allergology, Inselspital, Bern University Hospital, Bern, Switzerland

⁴Department of Medical Sciences, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia
Aleksandra Barac

⁵Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Jesper R. Davidsen

⁶Department of Respiratory Medicine, Pulmonary Aspergillosis Centre Denmark, Odense University Hospital, Odense, Denmark

⁷Department of Clinical Research, Odense Respiratory Research Unit, University of Southern Denmark, Odense, Denmark
Christian B. Laursen

⁶Department of Respiratory Medicine, Pulmonary Aspergillosis Centre Denmark, Odense University Hospital, Odense, Denmark

⁷Department of Clinical Research, Odense Respiratory Research Unit, University of Southern Denmark, Odense, Denmark
Ritesh Agarwal

⁸Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Inderpaul S. Sehgal

⁸Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Christoph Lange

⁹Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany

¹⁰German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany

¹¹Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany

¹²Baylor College of Medicine and Texas Children's Hospital, Global Tuberculosis Program, Houston, Texas
Helmut J.F. Salzer

¹Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine 4 - Pneumology, Kepler University Hospital, Linz, Austria

²Medical Faculty, Johannes Kepler University Linz, Linz, Austria

¹³Ignaz-Semmelweis-Institute, Interuniversity Institute for Infection Research, Vienna, Austria

Abstract

Post-tuberculosis lung disease (PTLD) has only recently been put in the spotlight as a medical entity. Recent data suggest that up to 50% of tuberculosis (TB) patients are left with PTLD-related impairment after completion of TB treatment. The presence of residual cavities in the lung is the largest risk factor for the development of chronic pulmonary aspergillosis (CPA) globally. Diagnosis of CPA is based on four criteria including a typical radiological pattern, evidence of Aspergillus species, exclusion of alternative diagnosis, and a chronic course of disease. In this manuscript, we provide a narrative review on CPA as a serious complication for patients with PTLD.

Keywords

post-tuberculosis disease - post-tuberculosis lung disease - chronic pulmonary aspergillosis - fungal infection - Aspergillus

Full Text

References

References
1 [Anonymous] Global tuberculosis report 2020. In: WHO; 2020
2 Allwood BW, Byrne A, Meghji J, Rachow A, van der Zalm MM, Schoch OD. Post-tuberculosis lung disease: clinical review of an under-recognised global challenge. Respiration 2021; 100 (08) 751-763
3 Denning DW, Cadranel J, Beigelman-Aubry C. et al; European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016; 47 (01) 45-68
4 Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J 2013; 41 (03) 621-626
5 Laursen CB, Davidsen JR, Van Acker L. et al. CPAnet registry-an international chronic pulmonary aspergillosis registry. J Fungi (Basel) 2020; 6 (03) 6
6 Baluku JB, Nuwagira E, Bongomin F, Denning DW. Pulmonary TB and chronic pulmonary aspergillosis: clinical differences and similarities. Int J Tuberc Lung Dis 2021; 25 (07) 537-546
7 Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J 2019; 54 (03) 54
8 Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One 2011; 6 (04) e17601
9 Dodd PJ, Yuen CM, Jayasooriya SM, van der Zalm MM, Seddon JA. Quantifying the global number of tuberculosis survivors: a modelling study. Lancet Infect Dis 2021; 21 (07) 984-992
10 Maier C, Chesov D, Schaub D. et al. Long-term treatment outcomes in patients with multidrug-resistant tuberculosis. Clin Microbiol Infect 2023; 29 (06) 751-757
11 Otto-Knapp R, Häcker B, Krieger D. et al. Long-term multidrug- and rifampicin-resistant tuberculosis treatment outcome by new WHO definitions in Germany. Eur Respir J 2022; 60 (05) 60
12 Linh NN, Viney K, Gegia M. et al. World Health Organization treatment outcome definitions for tuberculosis: 2021 update. Eur Respir J 2021; 58 (02) 58
13 Romanowski K, Baumann B, Basham CA, Ahmad Khan F, Fox GJ, Johnston JC. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2019; 19 (10) 1129-1137
14 Menzies NA, Quaife M, Allwood BW. et al. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. Lancet Glob Health 2021; 9 (12) e1679-e1687
15 Quaife M, Houben RMGJ, Allwood B. et al. Post-tuberculosis mortality and morbidity: valuing the hidden epidemic. Lancet Respir Med 2020; 8 (04) 332-333
16 Nightingale R, Carlin F, Meghji J. et al. Post-TB health and wellbeing. Int J Tuberc Lung Dis 2023; 27 (04) 248-283
17 Ahmad N, Javaid A, Syed Sulaiman SA. et al. Effects of multidrug resistant tuberculosis treatment on patients' health related quality of life: results from a follow up study. PLoS One 2016; 11 (07) e0159560
18 Daniels KJ, Irusen E, Pharaoh H, Hanekom S. Post-tuberculosis health-related quality of life, lung function and exercise capacity in a cured pulmonary tuberculosis population in the Breede Valley District, South Africa. S Afr J Physiother 2019; 75 (01) 1319
19 Muniyandi M, Rajeswari R, Balasubramanian R. et al. Evaluation of post-treatment health-related quality of life (HRQoL) among tuberculosis patients. Int J Tuberc Lung Dis 2007; 11 (08) 887-892
20 Rajeswari R, Muniyandi M, Balasubramanian R, Narayanan PR. Perceptions of tuberculosis patients about their physical, mental and social well-being: a field report from south India. Soc Sci Med 2005; 60 (08) 1845-1853
21 Meghji J, Gregorius S, Madan J. et al. The long term effect of pulmonary tuberculosis on income and employment in a low income, urban setting. Thorax 2021; 76 (04) 387-395
22 Igbokwe V, Ruby LC, Sultanli A, Bélard S. Post-tuberculosis sequelae in children and adolescents: a systematic review. Lancet Infect Dis 2023; 23 (04) e138-e150
23 Mpagama SG, Msaji KS, Kaswaga O. et al. The burden and determinants of post-TB lung disease. Int J Tuberc Lung Dis 2021; 25 (10) 846-853
24 Meghji J, Mortimer K, Agusti A. et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet 2021; 397 (10277): 928-940
25 Allwood B, van der Zalm M, Makanda G, Mortimer K. Steering Committee of the First International Post-Tuberculosis Symposium. The long shadow post-tuberculosis. Lancet Infect Dis 2019; 19 (11) 1170-1171
26 Amaral AF, Coton S, Kato B. et al; BOLD Collaborative Research Group. Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. Eur Respir J 2015; 46 (04) 1104-1112
27 Maleche-Obimbo E, Odhiambo MA, Njeri L. et al. Magnitude and factors associated with post-tuberculosis lung disease in low- and middle-income countries: a systematic review and meta-analysis. PLoS Glob Public Health 2022; 2 (12) e0000805
28 Visca D, Centis R, Munoz-Torrico M, Pontali E. Post-tuberculosis sequelae: the need to look beyond treatment outcome. Int J Tuberc Lung Dis 2020; 24 (08) 761-762
29 Rachow A, Ivanova O, Wallis R. et al. TB sequel: incidence, pathogenesis and risk factors of long-term medical and social sequelae of pulmonary TB - a study protocol. BMC Pulm Med 2019; 19 (01) 4
30 Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. Eur Respir Rev 2018; 27 (147) 27
31 Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB. Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis 2015; 32: 138-146
32 Meghji J, Simpson H, Squire SB, Mortimer K. A systematic review of the prevalence and pattern of imaging defined post-TB lung disease. PLoS One 2016; 11 (08) e0161176
33 Panda A, Bhalla AS, Sharma R. et al. Correlation of chest computed tomography findings with dyspnea and lung functions in post-tubercular sequelae. Lung India 2016; 33 (06) 592-599
34 Malherbe ST, Shenai S, Ronacher K. et al; Catalysis TB–Biomarker Consortium. Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med 2016; 22 (10) 1094-1100
35 Allwood BW, Stolbrink M, Baines N. et al. Persistent chronic respiratory symptoms despite TB cure is poorly correlated with lung function. Int J Tuberc Lung Dis 2021; 25 (04) 262-270
36 Pasipanodya JG, Miller TL, Vecino M. et al. Pulmonary impairment after tuberculosis. Chest 2007; 131 (06) 1817-1824
37 Ivanova O, Hoffmann VS, Lange C, Hoelscher M, Rachow A. Post-tuberculosis lung impairment: systematic review and meta-analysis of spirometry data from 14 621 people. Eur Respir Rev 2023; 32 (168) 32
38 Gai X, Allwood B, Sun Y. Post-tuberculosis lung disease and chronic obstructive pulmonary disease. Chin Med J (Engl) 2023; 136 (16) 1923-1928
39 Meghji J, Lesosky M, Joekes E. et al. Patient outcomes associated with post-tuberculosis lung damage in Malawi: a prospective cohort study. Thorax 2020; 75 (03) 269-278
40 Nightingale R, Chinoko B, Lesosky M. et al. Respiratory symptoms and lung function in patients treated for pulmonary tuberculosis in Malawi: a prospective cohort study. Thorax 2022; 77 (11) 1131-1139
41 Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet 2022; 399 (10342): 2227-2242
42 Xing Z, Sun T, Janssens JP. et al. Airflow obstruction and small airway dysfunction following pulmonary tuberculosis: a cross-sectional survey. Thorax 2023; 78 (03) 274-280
43 Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax 2000; 55 (01) 32-38
44 de Vallière S, Barker RD. Residual lung damage after completion of treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2004; 8 (06) 767-771
45 Ralph AP, Kenangalem E, Waramori G. et al. High morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: under-recognised phenomena. PLoS One 2013; 8 (11) e80302
46 Byrne AL, Marais BJ, Mitnick CD. et al. Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis. ERJ Open Res 2017; 3 (03) 3
47 Manji M, Shayo G, Mamuya S, Mpembeni R, Jusabani A, Mugusi F. Lung functions among patients with pulmonary tuberculosis in Dar es Salaam - a cross-sectional study. BMC Pulm Med 2016; 16 (01) 58
48 Devoid I, Sillah AK, Sutherland J. et al. The household economic burden of drug-susceptible TB diagnosis and treatment in The Gambia. Int J Tuberc Lung Dis 2022; 26 (12) 1162-1169
49 Günther G, Ithete S. Clinical care for patients with post-TB lung disease. Int J Tuberc Lung Dis 2021; 25 (03) 252-253
50 Cudahy PGT, Wilson D, Cohen T. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infect Dis 2020; 20 (01) 789
51 Theron G, Venter R, Calligaro G. et al. Xpert MTB/RIF results in patients with previous tuberculosis: can we distinguish true from false positive results?. Clin Infect Dis 2016; 62 (08) 995-1001
52 Fayos M, Silva JT, López-Medrano F, Aguado JM. Non-tuberculous mycobacteria and Aspergillus lung co-infection: systematic review. J Clin Med 2022; 11 (19) 11
53 Takeda K, Imamura Y, Takazono T. et al. The risk factors for developing of chronic pulmonary aspergillosis in nontuberculous mycobacteria patients and clinical characteristics and outcomes in chronic pulmonary aspergillosis patients coinfected with nontuberculous mycobacteria. Med Mycol 2016; 54 (02) 120-127
54 Khan R, Malik NI, Razaque A. Imaging of pulmonary post-tuberculosis sequelae. Pak J Med Sci 2020; 36 (01) S75-S82
55 van Kampen SC, Wanner A, Edwards M. et al. International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review. BMJ Glob Health 2018; 3 (04) e000745
56 Bongomin F. Post-tuberculosis chronic pulmonary aspergillosis: an emerging public health concern. PLoS Pathog 2020; 16 (08) e1008742
57 Hsu D, Irfan M, Jabeen K. et al. Post tuberculosis treatment infectious complications. Int J Infect Dis 2020; 92S: S41-S45
58 Rajpurohit R, Wagh P, Heda M, Dubey G, Gujar PS. Prevalence of chronic pulmonary aspergillosis in fibrocavitary pulmonary tuberculosis patients. J Family Med Prim Care 2023; 12 (01) 106-110
59 Menon B, Nima G, Dogra V, Jha S. Evaluation of the radiological sequelae after treatment completion in new cases of pulmonary, pleural, and mediastinal tuberculosis. Lung India 2015; 32 (03) 241-245
60 Qi Q, Wang W, Li T, Zhang Y, Li Y. Aetiology and clinical characteristics of patients with bronchiectasis in a Chinese Han population: a prospective study. Respirology 2015; 20 (06) 917-924
61 Dhar R, Singh S, Talwar D. et al. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. Lancet Glob Health 2019; 7 (09) e1269-e1279
62 Anwar GA, McDonnell MJ, Worthy SA. et al. Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. Respir Med 2013; 107 (07) 1001-1007
63 Pasteur MC, Helliwell SM, Houghton SJ. et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162 (4 Pt 1): 1277-1284
64 Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37 (Suppl. 03) S265-S280
65 Lowes D, Al-Shair K, Newton PJ. et al. Predictors of mortality in chronic pulmonary aspergillosis. Eur Respir J 2017; 49 (02) 49
66 Agarwal R, Vishwanath G, Aggarwal AN, Garg M, Gupta D, Chakrabarti A. Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses 2013; 56 (05) 559-570
67 Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 2011; 37 (04) 865-872
68 Singla R, Singhal R, Rathore R. et al. Risk factors for chronic pulmonary aspergillosis in post-TB patients. Int J Tuberc Lung Dis 2021; 25 (04) 324-326
69 Nguyen NTB, Le Ngoc H, Nguyen NV. et al. Chronic pulmonary aspergillosis situation among post tuberculosis patients in Vietnam: an observational study. J Fungi (Basel) 2021; 7 (07) 7
70 Kwizera R, Katende A, Bongomin F, Nakiyingi L, Kirenga BJ. Misdiagnosis of chronic pulmonary aspergillosis as pulmonary tuberculosis at a tertiary care center in Uganda: a case series. J Med Case Rep 2021; 15 (01) 140
71 Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 2011; 89 (12) 864-872
72 Agarwal R, Denning DW, Chakrabarti A. Estimation of the burden of chronic and allergic pulmonary aspergillosis in India. PLoS One 2014; 9 (12) e114745
73 Denning DW, Cole DC, Ray A. New estimation of the prevalence of chronic pulmonary aspergillosis (CPA) related to pulmonary TB - a revised burden for India. IJID Reg 2022; 6: 7-14
74 Kwizera R, Parkes-Ratanshi R, Page ID. et al. Elevated Aspergillus-specific antibody levels among HIV infected Ugandans with pulmonary tuberculosis. BMC Pulm Med 2017; 17 (01) 149
75 Oladele RO, Irurhe NK, Foden P. et al. Chronic pulmonary aspergillosis as a cause of smear-negative TB and/or TB treatment failure in Nigerians. Int J Tuberc Lung Dis 2017; 21 (09) 1056-1061
76 Hedayati MT, Azimi Y, Droudinia A. et al. Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran. Eur J Clin Microbiol Infect Dis 2015; 34 (09) 1759-1765
77 Salzer HJ, Heyckendorf J, Kalsdorf B, Rolling T, Lange C. Characterization of patients with chronic pulmonary aspergillosis according to the new ESCMID/ERS/ECMM and IDSA guidelines. Mycoses 2017; 60 (02) 136-142
78 Salzer HJF, Wang JY. Chronic pulmonary aspergillosis as a sequel to pulmonary TB. Int J Tuberc Lung Dis 2021; 25 (07) 519-520
79 Ngah V, Maud P, Baines N. et al. Respiratory presentations to acute services at a tertiary hospital in South Africa. S Afr Med J 2021; 111 (11) 1104-1109
80 Lakoh S, Kamara JB, Orefuwa E. et al. Prevalence and predictors of Aspergillus seropositivity and chronic pulmonary aspergillosis in an urban tertiary hospital in Sierra Leone: a cross-sectional study. PLoS Negl Trop Dis 2023; 17 (07) e0011284
81 Rozaliyani A, Setianingrum F, Azahra S. et al. Performance of LDBio Aspergillus WB and ICT antibody detection in chronic pulmonary aspergillosis. J Fungi (Basel) 2021; 7 (04) 7
82 Mohamed A, Obanda BA, Njeri HK. et al. Serological evidence of chronic pulmonary aspergillosis in tuberculosis patients in Kenya. BMC Infect Dis 2022; 22 (01) 798
83 Setianingrum F, Rozaliyani A, Syam R. et al. Evaluation and comparison of automated and manual ELISA for diagnosis of chronic pulmonary aspergillosis (CPA) in Indonesia. Diagn Microbiol Infect Dis 2020; 98 (03) 115124
84 Rozaliyani A, Rosianawati H, Handayani D. et al. Chronic pulmonary aspergillosis in post tuberculosis patients in Indonesia and the role of LDBio Aspergillus ICT as part of the diagnosis scheme. J Fungi (Basel) 2020; 6 (04) 6
85 Maitre T, Cottenet J, Godet C. et al. Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis. Eur Respir J 2021; 58 (02) 58
86 Godet C, Alastruey-Izquierdo A, Flick H. et al; CPAnet. A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention. J Antimicrob Chemother 2018; 73 (02) 280-286
87 Denning DW, Page ID, Chakaya J. et al. Case definition of chronic pulmonary aspergillosis in resource-constrained settings. Emerg Infect Dis 2018; 24 (08) 24
88 Hou X, Zhang H, Kou L, Lv W, Lu J, Li J. Clinical features and diagnosis of chronic pulmonary aspergillosis in Chinese patients. Medicine (Baltimore) 2017; 96 (42) e8315
89 Salzer HJF, Lange C, Hönigl M. [Aspergillus in airway material : ignore or treat?]. Internist (Berl) 2017; 58 (11) 1150-1162
90 Salzer HJF, Prattes J, Flick H. et al. Evaluation of galactomannan testing, the Aspergillus-specific lateral-flow device test and levels of cytokines in bronchoalveolar lavage fluid for diagnosis of chronic pulmonary aspergillosis. Front Microbiol 2018; 9: 2223
91 Page ID, Baxter C, Hennequin C. et al. Receiver operating characteristic curve analysis of four Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis. Diagn Microbiol Infect Dis 2018; 91 (01) 47-51
92 Salzer HJF, Reimann M, Oertel C. et al; CPAnet. Aspergillus-specific IgG antibodies for diagnosing chronic pulmonary aspergillosis compared to the reference standard. Clin Microbiol Infect 2023 ;7:S1198-743X(23)00416-0
93 Sehgal IS, Choudhary H, Dhooria S. et al. Diagnostic cut-off of Aspergillus fumigatus-specific IgG in the diagnosis of chronic pulmonary aspergillosis. Mycoses 2018; 61 (10) 770-776
94 Polverino E, Goeminne PC, McDonnell MJ. et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50 (03) 50
95 Salzer HJ, Cornely OA. Awareness of predictors of mortality may help improve outcome in chronic pulmonary aspergillosis. Eur Respir J 2017; 49 (02) 49
96 Koyama K, Ohshima N, Suzuki J. et al. Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles. J Infect Chemother 2014; 20 (06) 375-379
97 Rodriguez-Goncer I, Harris C, Kosmidis C, Muldoon EG, Newton PJ, Denning DW. Assessment of posaconazole salvage therapy in chronic pulmonary aspergillosis using predefined response criteria. Int J Antimicrob Agents 2018; 52 (02) 258-264
98 Sehgal IS, Dhooria S, Muthu V, Prasad KT, Agarwal R. An overview of the available treatments for chronic cavitary pulmonary aspergillosis. Expert Rev Respir Med 2020; 14 (07) 715-727
99 Sehgal IS, Dhooria S, Muthu V. et al. Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India. Lancet Infect Dis 2022; 22 (07) 1052-1061
100 Van Braeckel E, Page I, Davidsen JR. et al; CPAnet. Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement. Eur Respir J 2022; 59 (06) 59
101 Alastruey-Izquierdo A, Cadranel J, Flick H. et al; on behalf of CPAnet. Treatment of chronic pulmonary aspergillosis: current standards and future perspectives. Respiration 2018; 96 (02) 159-170
102 Bongomin F, Harris C, Hayes G, Kosmidis C, Denning DW. Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis. PLoS One 2018; 13 (04) e0193732
103 Shu CC, Wei YF, Chen KH. et al. inhaled corticosteroids increase risk of nontuberculous mycobacterial lung disease: a nested case-control study and meta-analysis. J Infect Dis 2022; 225 (04) 627-636
104 Muñoz-Torrico M, Rendon A, Centis R. et al. Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?. J Bras Pneumol 2016; 42 (05) 374-385
105 Lin H, Lin Y, Xiao L, Chen Y, Zeng X, Chang C. How do smoking status and smoking cessation efforts affect TB recurrence after successful completion of anti-TB treatment? A multicenter, prospective cohort study with a 7-year follow-up in China. Nicotine Tob Res 2021; 23 (12) 1995-2002